The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 408-414

  Van Agtmael, Michiel A ^a   Gupta, Veenu ^a   Van Der Graaf, Chantal A A ^a   Van Boxtel, Chris J ^a  

^a Dept of Clin Pharmacol/P ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; CYTOCHROME P450 ISOENZYME; DIHYDROARTEMISININ; UNCLASSIFIED DRUG; WATER;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FLUID INTAKE; FOOD DRUG INTERACTION; FRUIT JUICE; GRAPE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; ANTIMALARIALS; ANTIPROTOZOAL AGENTS; ARTEMISININS; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS; CROSS-OVER STUDIES; FOOD-DRUG INTERACTIONS; HUMANS; MALE; REFERENCE VALUES; SESQUITERPENES; TIME FACTORS;

EID: 0032723774     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101946     Document Type: Article

References (28)

1. 1. White NJ. Artemisinin: current status. Trans R Soc Trop Med Hyg 1994;88(suppl 1):3-4.
2. 2. Li GQ, Guo XB, Fu LC, Jian HX, Wang XH. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 1994;88(suppl 1):5-6.
3. 3. Ashton M, Sy ND, Gordi T, Hai TN, Thach DC, Huong NV, et al. Evidence for time-dependent artemisinin kinetics in adults with uncomplicated malaria. Pharm Pharmacol Lett 1996;3:127-30.
4. 4. Hassan Alin M, Ashton M, Kihamia CM, Mtey GJ, Bjorkman A. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg 1996;90:61-5.
5. 5. Ashton M, Hai TN, Sy ND, Huong DX, van Huong N, Nieu NT, et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 1998;26:25-7.
6. 6. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999;12:151-8.
7. 7. Svensson US, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Ngyuyen VH, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998; 64:160-7.
8. 8. Strolin-Benedetti M, Dostert P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994;102:101-5.
9. 9. Li RC, Narang PK, Poggesi I, Strolin-Benedetti M, A model-based assessment of redistribution-dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos 1996;17:223-36.
10. 10. Scheyer RD, Cramer JA, Mattson RH. A pharmacodynamic approach to the estimate of carbamazepine autoinduction. J Pharm Sci 1994;83:491-4.
11. 11. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;33:103-21.
12. 12. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-72.
13. 13. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
14. 14. van Agtmael MA, Gupta V, van der Wösten TH, Rutten JPB, van Boxtel CJ. Grapefruit juice increases the oral bioavailability of artemether. Eur J Clin Pharmacol 1999;55:405-10.
15. 15. Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998;10:354-9.
16. 16. Hollander AA, van Rooij J, Lentjes GW, Arbouw F, van Brce JB, Schoemakcr RC, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995;57:318-24.
17. 17. van Agtmael MA, Butter JJ, Portier EJG, van Boxtel CJ. Validation of an improved reversed phase high performance liquid chromatography assay with reductive electrochemical detection for the determination of artemisinin derivatives in man. Ther Drug Monit 1998;20:109-16.
18. 18. Scientist for experimental data fitting. Scientist Handbook ed. Salt Lake City (UT): Micromath; 1986.
19. 19. van Agtmael MA, van der Graaf CAA, Dien TK, Koopmans RP, van Boxtel CJ. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet 1998;23:429-36.
20. 20. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991.
21. 21. Grace JM, Aguilar AJ, Trotman KM, Peggins JO, Brewer TG. Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450 [published erratum appears in Drug Metab Dispos 1998 Jul;26:704]. Drug Metab Dispos 1998;26:313-7.
22. 22. Baune B, Furlan V, Taburet AM, Farinotti R. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human microsomes. Drug Metab Dispos 1999;27:565-8.
23. 23. Bangchang KN, Karbwang J, Back DJ. Mefloquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992;43:1957-61.
24. 24. Bangchang KN, Karbwang J, Back DJ. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992;44:587-90.
25. 25. Baker JK, McChesney JD, Chi HT. Decomposition of arteether in simulated stomach acid yielding compounds retaining antimalarial activity. Pharm Res 1993;10:662-6.
26. 26. Svenson USH, Sandstrom R, Carlborg O, Lennernas H, Ashton M. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1999;27:227-32.
27. 27. Karbwang J, Na-Bangchang K, Congpuong K, Molunto P, Thanavibul A. Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur J Clin Pharmacol 1997;52:307-10.
28. 28. Brewer TG, Grate SJ, Peggins JO, Weina PJ, Petras JM, Levine BS, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994;51:251-9.